The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase Ib study of ramucirumab and irinotecan for metastatic gastric cancer previously treated with fluoropyrimidine with/without platina and taxane.
 
Tamotsu Sagawa
No Relationships to Disclose
 
Hironaga Satake
No Relationships to Disclose
 
Koshi Fujikawa
No Relationships to Disclose
 
Yukimasa Hatachi
No Relationships to Disclose
 
Hisateru Yasui
No Relationships to Disclose
 
Masahito Kotaka
Honoraria - Chugai Pharma; Lilly Japan; Merck Serono; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Takeshi Kato
Consulting or Advisory Role - Chugai Pharma
Speakers' Bureau - Bayer; Chugai Pharma; Lilly; Taiho Pharmaceutical; Takeda
 
Akihito Tsuji
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Lilly; Taiho Pharmaceutical; Takeda